A study published in JAMA Cardiology July 24 suggests high-intensity statin use after MI depends on where patients live in the U.S., with 66% higher use in New England than in the country’s West South Central region.

Young people who used their smartphone five or more hours per day were 43% more likely to be obese than their counterparts with less reported screen time in a recent study presented at the ACC Latin American Conference 2019 in Cartagena, Colombia.

Australian researchers have uncovered yet another link between the controversial Paleolithic diet and heart disease.

The FDA on July 15 approved Sun Pharmaceutical Industries’ sprinkle formulation of rosuvastatin, an alternative to traditional lipid-lowerers for patients who have difficulty swallowing.

Toward the end of June, around a dozen American diabetics took an 817-mile caravan ride from Minneapolis to London, Ontario, in an effort to obtain more affordable insulin, CBS News reports. It was the second caravan in two months to make the trip.

Abbott Laboratories is planning to increase production of its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the coming years, Reuters reported July 16.

A study published in the New England Journal of Medicine July 18 suggests it may be time for the medical community to rethink its perception of diastolic blood pressure, which has long been considered inferior to systolic BP as a measure of cardiovascular wellness.

Massachusetts-based Azurity Pharmaceuticals announced July 10 it had received FDA approval for Katerzia Oral Suspension, making the drug the first and only FDA-approved amlodipine oral suspension to hit the commercial market.